Civica
Financial intelligence for Asia's healthcare markets
 
 
Remember me:

Analysis: The opportunities of diabetes in Asia

“The Asia-Pacific region presents lucrative opportunities for multinational pharmaceutical firms that treat diabetes,” says BMI Research in Singapore in a new report on healthcare in Asia. Fuelled by rapid urbanisation, nutrition transition and increasingly sedentary lifestyles, the epidemic has grown in parallel with the worldwide rise in obesity. Asia’s large population and rapid economic development have made it an epicentre of the epidemic, with India and China the key hotspots in the region, it explains.

The World Health Organisation (WHO) reckons that 80% of diabetes deaths occur in low- and middle-income countries, and forecasts that these deaths will double between 2016 and 2030. The epidemic of diabetes, as well as the burden of related non-communicable diseases, is challenging public health and hospital systems around the world – particularly in the Asia-Pacific region. Though the prevalence of obesity in Asia is relatively low compared with that across Western populations, BMI argues that Asia Pacific’s vast population and rapid economic development presents significant opportunities for companies in diabetes therapeutic field.

The size of the problem is significant. Patients with diabetes in Asia now account for more than 60% of the global diabetic population, with the majority residing in the largest and most populous countries; India and China.

 “We note that India and China are by far the two largest markets in the region for diabetes medicines,” writes BMI. According to International Diabetes Federation, there were 69.1 million cases of diabetes in India in 2015 and 109 million cases of diabetes in China. Last year, India’s population lost 9.2 million disability-adjusted life years to diabetes, China lost 8.2 million years and Indonesia lost 2.9 million years. “The significant increase in the prevalence of diabetes in India and China has occurred over a short period of time, largely driven by sedentary lifestyles and unhealthy diets,” it adds.

Due to elevated behavioural risks causing a strain on the region’s healthcare systems, governments have begun to introduce initiatives aimed at reversing this trend. Moreover, given the high financial burden of treating diabetes, there will be greater emphasis placed on preventative care. In India, BMI cites a national programme for control of diabetes has been rolled out across the country, to improve diabetes awareness levels at a national level. The government has also imposed a hefty tax of 28% on diabetes-inducing food substances under the Goods and Services Tax regime in an attempt to dissuade consumption of unhealthy food. And in China, World Diabetes Day and several similarly themed publicity events have been used to spread information on diabetes prevention and to raise public health literacy. Public health lifestyle campaigns have been pushed forward to advocate rational diet and adequate exercise, and to discourage smoking and the consumption of alcohol.

Posted on: 14/06/2017 UTC+08:00


News

Lilly Asia Ventures, which makes venture capital investments in Asia for global pharmaceutical giant Eli Lilly and Company, has closed LAV Biosciences Fund IV, its fourth fund. It took only two months to reach the hard cap of US$450 million.
Summerset Group, New Zealand’s third-largest listed retirement village operator, has posted a 78% jump in profits for the first half of the year of NZ$90.3 million (US$65.9 million).
Q&M Dental Group, which operates the largest network of private dental outlets in Singapore, has reported a decline in profits for the second quarter of the year, though these are the result of the deconsolidation of two subsidiaries.
Hong Kong-listed Common Splendor International Health Industry Group is currently juggling with two acquisitions in China.
IVD and medical imaging company Yestar Healthcare has said that it is in the preliminary stage of possibly acquiring medical device companies in the northern region of China.
Paragon Care, a leading distributor and manufacturer supplying medical equipment to hospitals, has agreed to acquire Medtek for A$649,000 (US$512,759) shares and cash. The company provides biomedical engineering services and preventative maintenance to the medical, scientific, aged care and allied health clients in the Far North Queensland region.
Hospital operation and management group the Hospital Corporation of China (HCC) plans to buy a 70% stake in an unnamed traditional Chinese medicine private hospital in Zhejiang.
For the first half of the year private specialist healthcare provider Singapore Medical Group (SMG) has reported a massive jump in profits on the back of its move into diagnostics and aesthetics.



Analysis

Mercer’s Catherine Li explains how companies in China can avoid common pitfalls when they establish employee health management programmes.
Lieven Jacquemyn, PPP international development director at GE Healthcare Singapore, discusses how governments, providers and investors can work together to bring universal health coverage to the region.
Mercer’s Rose Kwan and Heena Sethi explain how employers can better manage their healthcare benefits.
Susann Roth, senior social development specialist, Asian Development Bank, looks at financing mechanisms to meet the third Sustainable Development Goal.
On the back of an ageing population, strong employment growth and the flow of private investment, medical and health care property will emerge as a major asset class in Western Australian’s commercial property markets according to new analysis by independent West Australian commercial property information and research firm, Y Research.
In the second part of our two-part series, Bart Van den Mooter, CEO of the TforG Group, and Helgert van Raamt, vp partnerships and new business at TforG Group, look at the medtech opportunities in China.
In part one of a two-part series, Bart Van den Mooter, CEO of the TforG Group, and Helgert van Raamt, vp partnerships and new business at TforG Group, look at the impact of reforms on medtech in China.
In what is starting to resemble a comedy of errors, Wenzhou Kangning Hospital, the largest private psychiatric specialty care service provider in China, is having to start work yet again for its A-share offering.


Civica

HealthInvestor Asia Summit

AON

Podcasts

Hedge Fund Focus

HealthInvestor Asia twitter feed
HIA Indices